 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||| alprostadil liposome / CSPC Pharma
Enrollment open: A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI (clinicaltrials.gov) - Oct 28, 2022
P2, N=368, Recruiting, Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Not yet recruiting --> Recruiting
- ||||| alprostadil liposome / CSPC Pharma
New P2 trial: A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI (clinicaltrials.gov) - Jul 27, 2022
P2, N=368, Not yet recruiting, Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- || alprostadil liposome / CSPC Pharma
New P2 trial: Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran (clinicaltrials.gov) - Dec 12, 2019
P2, N=20, Recruiting, Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- | alprostadil liposome / CSPC Pharma
New P1 trial: The Safety and Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers (clinicaltrials.gov) - Sep 13, 2018
P1, N=48, Recruiting, Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- |||| alprostadil liposome / CSPC Pharma
Enrollment open: A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans (clinicaltrials.gov) - Mar 10, 2017
P2, N=160, Recruiting, Sponsor: Guangzhou Yipinhong Pharmaceutical CO.,LTD
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | alprostadil liposome / CSPC Pharma
New P1 trial: The Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers (clinicaltrials.gov) - Sep 7, 2016
P1, N=44, Completed, Sponsor: Guangzhou Yipinhong Pharmaceutical CO.,LTD
- ||||| alprostadil liposome / CSPC Pharma
New P2 trial: A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans (clinicaltrials.gov) - Aug 23, 2016
P2, N=160, Not yet recruiting, Sponsor: Guangzhou Yipinhong Pharmaceutical CO.,LTD